494222-19-4

Upstream product

• 494224-45-2 2-[(2R)-2-({tert-butyldimethylsilyloxy}methyl)-5-oxo-1-pyrrolidinyl]ethyl methanesulfonate 
• 492471-45-1 9-oxo-13-hydroxy-14,15,16,17,18,19,20-heptanor-5-thia-8-azaprostanoic acid methyl ester 
• 492471-47-3 9-oxo-12-formyl-13,14,15,16,17,18,19,20-octanor-5-thia-8-azaprostanoic acid methyl ester 
• 128899-30-9 (R)-5-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-2-one 
• 1369917-57-6 methyl 4-({2-[(2R)-2-{(1E)-4-[3-(methoxymethyl)phenyl]-3-oxo-1-buten-1-yl}-5-oxo-1-pyrrolidinyl]ethyl}thio)butanoate 
• 494224-24-7 methyl 4-[(2-{(2R)-2-[(tert-butyldimethylsilyloxy)methyl]-5-oxo-1-pyrrolidinyl}ethyl)thio]butanoate 
• 494224-23-6 S-(2-{(2R)-2-[(tert-butyldimethylsilyloxy)methyl]-5-oxo-1-pyrrolidinyl}ethyl)ethanethioate 
• 494224-21-4 methyl (R)-2-(2-(((tert-butyldimethylsilyl)oxy)methyl)-5-oxopyrrolidin-1-yl)acetate 

Relevant academic research and scientific papers

Discovery of an 8-aza-5-thiaProstaglandin E1 analog as a highly selective EP4 receptor agonist

For the purpose of discovering an orally available EP4 subtype-selective agonist, a series of 8-aza prostaglandin E1 (PGE1) analogs were synthesized and evaluated for their affinity for PGE2 receptor subtypes. Additionally

REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT

A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound